Bionano Genomics is listed under Measuring and Control category by Fama And French industry classification. In 2019, BNGO's revenue was $10.13 million, a decrease of -15.59% compared to the previous year's $12.00 million. I actually have a masters degree in biochemistry, and I can tell you that this is actually quite interesting. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics … For a company who is supposed to be at the edge of science, I want to see increased funding for the research and development, but that could be a bit biased because like I said, my day job is a scientist. Proprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr Proprietary scoring... Bionano Genomics makes Saphyr, a genome imaging tool. Maybe, but I wouldn’t be surprised if we see more upside to the stock first, because of the incredible momentum we got going on here. Past performance The stock may cool off, but it looks like there are many chapters to come for the firm. Now, normally when i say FOMO investors are jumping in, I normally say “and then valuation concerns caused the stock to drop”. I would want to see my companies steadily grow revenues year over year, and I want to see a deceleration of Sales, General and Administrative spending. I actually have a masters degree in biochemistry, and I can tell you that this is actually quite interesting. I’ve mentioned this a few times in the past, but I don’t like seeing rises in Sales, General and Administrative (SG&A) spending because this is like the back office work. BNGO stock is on the high side right now, especially since it will likely take time for the company's system to get traction. These expenses are for covering the accountants, the lawyers, and the big boss’s business trips to 5 star hotels in Hawaii. A dazzling BNGO stock has flown under the radar in 2021, but don't expect shares of this newly-minted mid-cap to remain a secret. Now I don’t understand Saphyr’s technology, I couldn’t find any real public or free publications about the science of Bionano. This may be a little boring, but it’s important to understand exactly what you’re investing your money into. Start a 14-day free trial to Morningstar Premium to unlock our take on BNGO. In my opinion, Bionano Genomics is certainly an interesting company and is becoming a leader in the hot tech field. The latest company information relevant to the individual and institutional investor includes stock … These popular companies have rallied between 1,000% and 2,400% since late July. However, the fundamentals of the company leave a little to be desired. This high-flying stock is already one of the biggest winners in the new year. I’ve mentioned this a few times in the past, but I don’t like seeing rises in Sales, General and Administrative (SG&A) spending because this is like the back office work. The post The Sequence to More Highs is Unfolding in BNGO Stock... BioNano has a promising clinical platform. As always, we encourage Bionano Genomics, Inc. (BNGO) closed at $11.80 in the latest trading session, marking a +1.29% move from the prior day. BNGO 7.15 0.25 (3.62%). Cathie Wood has a great track record and she clearly does her homework. Why is this? • Rising Costs - The next thing I want to point out here on the statement of operations is the rising costs that Bionano is incurring. Well, now the writing’s on the wall…. There are many doctors out there who also think that this tech is real and would be revolutionary for the future, and we had some good news on doctors being able to use the Saphyr tech being used to map the genome and better understand the health crisis of what’s been going on since March, and also for autism and tumor research. NEW YORK, March 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPGN, GME, JNJ, BNGO, and SINT. Now i’ll put up a screenshot from a different part of the earnings report if we scroll down, but Bionano stated that the reasons for the dropped revenue is due to the ongoing health crisis. Should you invest in BNGO? Please be careful when buying a stock from a post that has 500 karma and 15+ awards in the past hour. Here's what you should know about Bionano Genomics now. These high-flying stocks have been moneymakers since early November. Post-Market 0.51 (7.13%) Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA. If you're bullish on genomics, you should be bullish on this stock. Cathie Wood has a great track record and she clearly does her homework. But, you know, don’t just listen to me. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Bionano Genomics takes advantage of a spike to sell shares at highs. A few Quick fundamentals to make BNGO more attractive - Insider Ownership is slightly above average - BNGO Insider Trading Report - Bionano Genomics… This may be a little boring, but it’s important to understand exactly what you’re investing your money into. - Bionano is incredibly momentum driven at the moment, likely pushed with the help of Cathie Wood and her Ark Investments, using the ARKG ETF for innovative genomics. In 2020, shares of the genome analysis company soared 148%. Click here to visit TheStockStudents Youtube channel! But what I can tell you, is that the concept of Saphyr’s tech is not really new. This is why I think this is a red flag here. Just to flex my biochemistry masters degree a little and explain what Saphyr is, basically, nearly all of our cells in our body (except for red blood cells), have DNA in it, and the DNA is stored in something called a chromosome, which looks like this. ET by Jaimy Lee Bionano Genomics stock price target … Bionano Genomics (BNGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. To me, even though I understand the magnitude of disruption that this health crisis is causing, I don’t think this is the only reason for decline in revenues, and I’m not sure what else is causing it. Rumors came as an ARK Invest analyst, Simon Barnett on Twitter tweeted that he would like to talk to Bionano’s CEO Erik Holmlin. So to me, it appears that we had the early retail investors jump in around the beginning here, then we started capturing the FOMO investors in the past few days. But in this case, yes valuation is a concern to me at 1.5 billion even though I'll show you we’re only making a couple million in revenues when we get to the earnings report, but I don’t think it’s actually too bad here at 1 billion dollars.